ASCO 2024 | Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancer

Stephanie Lheureux, MD, PhD, University of Toronto, Toronto, Canada, discusses future applications of PARP inhibitors in neoadjuvant therapy, aiming for a chemotherapy-free approach. The NEO trial (NCT02489006) began before PARP inhibitors were used in first-line treatment. Dr Lheureux highlights the need for new strategies, possibly involving next-generation PARP inhibitors or combinations, especially for patients with prior exposure. Careful patient selection is crucial for the success of this neoadjuvant strategy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.